Nima Rezaei, MD, PhD, is Professor of Clinical Immunology and Allergy at Tehran University of Medical Sciences, where he also serves as Associate Dean of International Affairs for the School of Medicine and Director of the Global Academic Program. He is Deputy President of the Research Center for Immunodeficiencies and holds an affiliated research appointment in the Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet, Sweden. He earned his MD from Tehran University of Medical Sciences and his PhD in Clinical Immunology and Human Genetics from the University of Sheffield, United Kingdom. His research addresses primary immunodeficiencies and translational immunology, with recent work extending into computational and AI-based approaches to immune profiling. He is the founder and President of the Universal Scientific Education and Research Network (USERN) and serves as co-editor of the Springer Nature series Advances in Experimental Medicine and Biology.Mahsa Keshavarz-Fathi is a medical researcher and MD candidate at Tehran University of Medical Sciences (TUMS). She is also the managing director of the Cancer Immunology Project (CIP) and Breast Cancer Association (BrCA) undertaking and managing different research projects in the field of cancer treatment, cancer immunology and immunotherapy.

• 1. Cancer immunology2. Immunotherapeutic Approaches in Cancer3. Vaccines, Adjuvants, and Delivery Systems4. Tumor Antigens 5. Strategy of Allogeneic and Autologous Cancer Vaccines6. Personalized Cancer Vaccine7. Whole Tumor Cell Vaccine for Cancer8. Peptide and Protein Vaccines for Cancer9. Immune Cell Vaccine for Cancer10. Genetic Vaccine for Cancer11. Candidate Cancers for Vaccination12. Obstacles in the Development of Therapeutic Cancer Vaccines13. Combination Therapy: Cancer Vaccines and Other Therapeutics14. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines

Nima Rezaei, MD, PhD, is Professor of Clinical Immunology and Allergy at Tehran University of Medical Sciences, where he also serves as Associate Dean of International Affairs for the School of Medicine and Director of the Global Academic Program. He is Deputy President of the Research Center for Immunodeficiencies and holds an affiliated research appointment in the Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet, Sweden. He earned his MD from Tehran University of Medical Sciences and his PhD in Clinical Immunology and Human Genetics from the University of Sheffield, United Kingdom. His research addresses primary immunodeficiencies and translational immunology, with recent work extending into computational and AI-based approaches to immune profiling. He is the founder and President of the Universal Scientific Education and Research Network (USERN) and serves as co-editor of the Springer Nature series Advances in Experimental Medicine and Biology.Mahsa Keshavarz-Fathi is a medical researcher and MD candidate at Tehran University of Medical Sciences (TUMS). She is also the managing director of the Cancer Immunology Project (CIP) and Breast Cancer Association (BrCA) undertaking and managing different research projects in the field of cancer treatment, cancer immunology and immunotherapy.

• 1. Cancer immunology2. Immunotherapeutic Approaches in Cancer3. Vaccines, Adjuvants, and Delivery Systems4. Tumor Antigens 5. Strategy of Allogeneic and Autologous Cancer Vaccines6. Personalized Cancer Vaccine7. Whole Tumor Cell Vaccine for Cancer8. Peptide and Protein Vaccines for Cancer9. Immune Cell Vaccine for Cancer10. Genetic Vaccine for Cancer11. Candidate Cancers for Vaccination12. Obstacles in the Development of Therapeutic Cancer Vaccines13. Combination Therapy: Cancer Vaccines and Other Therapeutics14. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines

Nima Rezaei, MD, PhD, is Professor of Clinical Immunology and Allergy at Tehran University of Medical Sciences, where he also serves as Associate Dean of International Affairs for the School of Medicine and Director of the Global Academic Program. He is Deputy President of the Research Center for Immunodeficiencies and holds an affiliated research appointment in the Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet, Sweden. He earned his MD from Tehran University of Medical Sciences and his PhD in Clinical Immunology and Human Genetics from the University of Sheffield, United Kingdom. His research addresses primary immunodeficiencies and translational immunology, with recent work extending into computational and AI-based approaches to immune profiling. He is the founder and President of the Universal Scientific Education and Research Network (USERN) and serves as co-editor of the Springer Nature series Advances in Experimental Medicine and Biology.Mahsa Keshavarz-Fathi is a medical researcher and MD candidate at Tehran University of Medical Sciences (TUMS). She is also the managing director of the Cancer Immunology Project (CIP) and Breast Cancer Association (BrCA) undertaking and managing different research projects in the field of cancer treatment, cancer immunology and immunotherapy.

• 1. Cancer immunology2. Immunotherapeutic Approaches in Cancer3. Vaccines, Adjuvants, and Delivery Systems4. Tumor Antigens 5. Strategy of Allogeneic and Autologous Cancer Vaccines6. Personalized Cancer Vaccine7. Whole Tumor Cell Vaccine for Cancer8. Peptide and Protein Vaccines for Cancer9. Immune Cell Vaccine for Cancer10. Genetic Vaccine for Cancer11. Candidate Cancers for Vaccination12. Obstacles in the Development of Therapeutic Cancer Vaccines13. Combination Therapy: Cancer Vaccines and Other Therapeutics14. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines